27241818|t|Group III/IV muscle afferents limit the intramuscular metabolic perturbation during whole body exercise in humans
27241818|a|The purpose of this study was to determine the role of group III/IV muscle afferents in limiting the endurance exercise - induced metabolic perturbation assayed in muscle biopsy samples taken from locomotor muscle. Lumbar intrathecal fentanyl was used to attenuate the central projection of μ-opioid receptor - sensitive locomotor muscle afferents during a 5 km cycling time trial. The findings suggest that the central projection of group III/IV muscle afferent feedback constrains voluntary neural ' drive ' to working locomotor muscle and limits the exercise - induced intramuscular metabolic perturbation. Therefore, the CNS might regulate the degree of metabolic perturbation within locomotor muscle and thereby limit peripheral fatigue. It appears that the group III/IV muscle afferents are an important neural link in this regulatory mechanism, which probably serves to protect locomotor muscle from the potentially severe functional impairment as a consequence of severe intramuscular metabolic disturbance. To investigate the role of metabo - and mechanosensitive group III/IV muscle afferents in limiting the intramuscular metabolic perturbation during whole body endurance exercise, eight subjects performed 5 km cycling time trials under control conditions (CTRL) and with lumbar intrathecal fentanyl impairing lower limb muscle afferent feedback (FENT). Vastus lateralis muscle biopsies were obtained before and immediately after exercise. Motoneuronal output was estimated through vastus lateralis surface electromyography (EMG). Exercise - induced changes in intramuscular metabolites were determine d using liquid and gas chromatography-mass spectrometry. Quadriceps fatigue was quantified by pre - to post - exercise changes in potentiated quadriceps twitch torque (ΔQTsingle) evoked by electrical femoral nerve stimulation. Although motoneuronal output was 21 ± 12% higher during FENT compared to CTRL (P < 0.05), time to complete the time trial was similar (∼8.8 min). Compared to CTRL, power output during FENT was 10 ± 4% higher in the first half of the time trial, but 11 ± 5% lower in the second half (both P < 0.01). The exercise - induced increase in intramuscular inorganic phosphate, H(+), adenosine diphosphate, lactate and phosphocreatine depletion was 55 ± 30, 62 ± 18, 129 ± 63, 47 ± 14 (P < 0.001) and 27 ± 14% (P < 0.01) greater in FENT than CTRL. ΔQTsingle was greater following FENT than CTRL (-52 ± 2 vs -31 ± 1%, P < 0.001) and this difference was positively correlated with the difference in inorganic phosphate (r(2) = 0.79; P < 0.01) and H(+) (r(2) = 0.92; P < 0.01). In conclusion, during whole body exercise, group III/IV muscle afferents provide feedback to the CNS which, in turn, constrains motoneuronal output to the active skeletal muscle. This regulatory mechanism limits the exercise - induced intramuscular metabolic perturbation, preventing an abnormal homeostatic challenge and excessive peripheral fatigue.
27241818	0	19	Group III/IV muscle	T024	C0026845
27241818	20	29	afferents	T025	C0027883
27241818	30	35	limit	T169	C0439801
27241818	40	53	intramuscular	T082	C0442117
27241818	54	63	metabolic	T169	C0311400
27241818	64	76	perturbation	T169	C0332453
27241818	84	94	whole body	T017	C0444584
27241818	95	103	exercise	T056	C0015259
27241818	107	113	humans	T016	C0086418
27241818	118	125	purpose	T169	C1285529
27241818	134	139	study	T062	C2603343
27241818	147	156	determine	T059	C1148554
27241818	161	165	role	T077	C1705810
27241818	169	188	group III/IV muscle	T024	C0026845
27241818	189	198	afferents	T025	C0027883
27241818	202	210	limiting	T169	C0439801
27241818	215	224	endurance	T033	C0518031
27241818	225	233	exercise	T056	C0015259
27241818	236	243	induced	T169	C0205263
27241818	244	253	metabolic	T169	C0311400
27241818	254	266	perturbation	T169	C0332453
27241818	267	274	assayed	T059	C1510438
27241818	278	284	muscle	T024	C0026845
27241818	285	299	biopsy samples	T024	C0677862
27241818	311	320	locomotor	T040	C0023946
27241818	321	327	muscle	T024	C0026845
27241818	329	335	Lumbar	T029	C0024090
27241818	336	347	intrathecal	T030	C1370196
27241818	348	356	fentanyl	T109,T121	C0015846
27241818	369	378	attenuate	T052	C0599946
27241818	383	390	central	T082	C0205099
27241818	391	401	projection	T082	C0348018
27241818	405	422	μ-opioid receptor	T116,T192	C0066908
27241818	425	434	sensitive	T169	C0332324
27241818	435	444	locomotor	T040	C0023946
27241818	445	451	muscle	T024	C0026845
27241818	452	461	afferents	T025	C0027883
27241818	476	483	cycling	T079	C1511572
27241818	484	488	time	T079	C0040223
27241818	489	494	trial	T062	C0008976
27241818	500	508	findings	T033	C0243095
27241818	526	533	central	T082	C0205099
27241818	534	544	projection	T082	C0348018
27241818	548	567	group III/IV muscle	T024	C0026845
27241818	568	576	afferent	T025	C0027883
27241818	577	585	feedback	T039	C0678663
27241818	586	596	constrains	T077	C1707494
27241818	597	606	voluntary	T055	C0439656
27241818	607	613	neural	T169	C3714606
27241818	616	621	drive	T041	C0013126
27241818	627	634	working	T169	C0205177
27241818	635	644	locomotor	T040	C0023946
27241818	645	651	muscle	T024	C0026845
27241818	656	662	limits	T169	C0439801
27241818	667	675	exercise	T056	C0015259
27241818	678	685	induced	T169	C0205263
27241818	686	699	intramuscular	T082	C0442117
27241818	700	709	metabolic	T169	C0311400
27241818	710	722	perturbation	T169	C0332453
27241818	739	742	CNS	T022	C3714787
27241818	749	757	regulate	T038	C1327622
27241818	762	768	degree	T081	C0449286
27241818	772	781	metabolic	T169	C0311400
27241818	782	794	perturbation	T169	C0332453
27241818	802	811	locomotor	T040	C0023946
27241818	812	818	muscle	T024	C0026845
27241818	831	836	limit	T169	C0439801
27241818	837	847	peripheral	T082	C0205100
27241818	848	855	fatigue	T184	C0015672
27241818	860	867	appears	T080	C0700364
27241818	877	896	group III/IV muscle	T024	C0026845
27241818	897	906	afferents	T025	C0027883
27241818	914	923	important	T080	C3898777
27241818	924	930	neural	T169	C3714606
27241818	931	935	link	T030	C0178718
27241818	944	954	regulatory	T038	C1327622
27241818	955	964	mechanism	T169	C0441712
27241818	972	980	probably	T078	C0750492
27241818	991	998	protect	T033	C1545588
27241818	999	1008	locomotor	T040	C0023946
27241818	1009	1015	muscle	T024	C0026845
27241818	1025	1036	potentially	T080	C3245505
27241818	1037	1043	severe	T080	C0205082
27241818	1044	1065	functional impairment	T033	C4062321
27241818	1071	1082	consequence	T169	C0686907
27241818	1086	1092	severe	T080	C0205082
27241818	1093	1106	intramuscular	T082	C0442117
27241818	1107	1116	metabolic	T169	C0311400
27241818	1117	1128	disturbance	T080	C2699787
27241818	1133	1144	investigate	T169	C1292732
27241818	1149	1153	role	T077	C1705810
27241818	1157	1163	metabo	T040	C0025519
27241818	1170	1186	mechanosensitive	T080	C1522640
27241818	1187	1206	group III/IV muscle	T024	C0026845
27241818	1207	1216	afferents	T025	C0027883
27241818	1220	1228	limiting	T169	C0439801
27241818	1233	1246	intramuscular	T082	C0442117
27241818	1247	1256	metabolic	T169	C0311400
27241818	1257	1269	perturbation	T169	C0332453
27241818	1277	1287	whole body	T017	C0444584
27241818	1288	1297	endurance	T033	C0518031
27241818	1298	1306	exercise	T056	C0015259
27241818	1314	1322	subjects	T096	C0681850
27241818	1323	1332	performed	T169	C0884358
27241818	1338	1345	cycling	T079	C1511572
27241818	1346	1350	time	T079	C0040223
27241818	1351	1357	trials	T062	C0008976
27241818	1358	1382	under control conditions	T033	C2911690
27241818	1384	1388	CTRL	T033	C2911690
27241818	1399	1405	lumbar	T029	C0024090
27241818	1406	1417	intrathecal	T030	C1370196
27241818	1418	1426	fentanyl	T109,T121	C0015846
27241818	1427	1436	impairing	T169	C0221099
27241818	1437	1447	lower limb	T023	C0023216
27241818	1448	1454	muscle	T024	C0026845
27241818	1455	1463	afferent	T025	C0027883
27241818	1464	1472	feedback	T039	C0678663
27241818	1474	1478	FENT	T039	C0678663
27241818	1481	1497	Vastus lateralis	T023	C0224444
27241818	1498	1504	muscle	T024	C0026845
27241818	1505	1513	biopsies	T024	C0677862
27241818	1519	1527	obtained	T169	C1301820
27241818	1528	1534	before	T079	C0332152
27241818	1539	1550	immediately	T079	C0205253
27241818	1551	1556	after	T079	C0687676
27241818	1557	1565	exercise	T056	C0015259
27241818	1567	1579	Motoneuronal	T025	C0026609
27241818	1580	1600	output was estimated	T060	C0204709
27241818	1609	1633	vastus lateralis surface	T023	C0224444
27241818	1634	1650	electromyography	T060	C0013839
27241818	1652	1655	EMG	T060	C0013839
27241818	1658	1666	Exercise	T056	C0015259
27241818	1669	1676	induced	T169	C0205263
27241818	1677	1684	changes	T169	C0392747
27241818	1688	1701	intramuscular	T082	C0442117
27241818	1702	1713	metabolites	T123	C0870883
27241818	1719	1728	determine	T059	C1148554
27241818	1737	1743	liquid	T167	C0302908
27241818	1748	1784	gas chromatography-mass spectrometry	T059	C1720784
27241818	1786	1796	Quadriceps	T023	C0224440
27241818	1797	1804	fatigue	T184	C0015672
27241818	1809	1819	quantified	T081	C1709793
27241818	1823	1826	pre	T079	C0332152
27241818	1832	1836	post	T079	C0687676
27241818	1839	1847	exercise	T056	C0015259
27241818	1848	1855	changes	T169	C0392747
27241818	1859	1895	potentiated quadriceps twitch torque	T067	C0376590
27241818	1897	1906	ΔQTsingle	T067	C0376590
27241818	1908	1914	evoked	T080	C1444748
27241818	1918	1928	electrical	T169	C0442828
27241818	1929	1942	femoral nerve	T023	C0015808
27241818	1943	1954	stimulation	T061	C1292856
27241818	1965	1977	motoneuronal	T025	C0026609
27241818	1978	1984	output	T052	C0441655
27241818	1998	2004	higher	T080	C0205250
27241818	2012	2016	FENT	T039	C0678663
27241818	2017	2025	compared	T052	C1707455
27241818	2029	2033	CTRL	T033	C2911690
27241818	2046	2050	time	T079	C0040223
27241818	2054	2062	complete	T080	C0205197
27241818	2067	2071	time	T079	C0040223
27241818	2072	2077	trial	T062	C0008976
27241818	2082	2089	similar	T080	C2348205
27241818	2102	2110	Compared	T052	C1707455
27241818	2114	2118	CTRL	T033	C2911690
27241818	2120	2132	power output	T070	C0445194
27241818	2140	2144	FENT	T039	C0678663
27241818	2157	2163	higher	T080	C0205250
27241818	2171	2181	first half	T033	C3843058
27241818	2189	2193	time	T079	C0040223
27241818	2194	2199	trial	T062	C0008976
27241818	2213	2218	lower	T080	C0205251
27241818	2226	2237	second half	T033	C3843057
27241818	2259	2267	exercise	T056	C0015259
27241818	2270	2277	induced	T169	C0205263
27241818	2278	2286	increase	T169	C0442805
27241818	2290	2303	intramuscular	T082	C0442117
27241818	2304	2323	inorganic phosphate	T121,T197	C0031603
27241818	2325	2329	H(+)	T196	C0033727
27241818	2331	2352	adenosine diphosphate	T114,T123	C0001459
27241818	2354	2361	lactate	T109	C0022924
27241818	2366	2381	phosphocreatine	T116,T121,T123	C0031634
27241818	2382	2391	depletion	T169	C0333668
27241818	2468	2475	greater	T081	C1704243
27241818	2479	2483	FENT	T039	C0678663
27241818	2489	2493	CTRL	T033	C2911690
27241818	2495	2504	ΔQTsingle	T067	C0376590
27241818	2509	2516	greater	T081	C1704243
27241818	2527	2531	FENT	T039	C0678663
27241818	2537	2541	CTRL	T033	C2911690
27241818	2584	2594	difference	T081	C1705241
27241818	2599	2609	positively	T033	C1446409
27241818	2610	2620	correlated	T080	C1707520
27241818	2630	2640	difference	T081	C1705241
27241818	2644	2663	inorganic phosphate	T121,T197	C0031603
27241818	2725	2735	conclusion	T078	C1707478
27241818	2744	2754	whole body	T017	C0444584
27241818	2755	2763	exercise	T056	C0015259
27241818	2765	2784	group III/IV muscle	T024	C0026845
27241818	2785	2794	afferents	T025	C0027883
27241818	2795	2802	provide	T052	C1999230
27241818	2803	2811	feedback	T039	C0678663
27241818	2819	2822	CNS	T022	C3714787
27241818	2839	2849	constrains	T077	C1707494
27241818	2850	2862	motoneuronal	T025	C0026609
27241818	2863	2869	output	T052	C0441655
27241818	2877	2883	active	T169	C0205177
27241818	2884	2899	skeletal muscle	T024	C0242692
27241818	2906	2916	regulatory	T038	C1327622
27241818	2917	2926	mechanism	T169	C0441712
27241818	2927	2933	limits	T169	C0439801
27241818	2938	2946	exercise	T056	C0015259
27241818	2949	2956	induced	T169	C0205263
27241818	2957	2970	intramuscular	T082	C0442117
27241818	2971	2980	metabolic	T169	C0311400
27241818	2981	2993	perturbation	T169	C0332453
27241818	3009	3029	abnormal homeostatic	T033	C4022950
27241818	3030	3039	challenge	T058	C0805586
27241818	3044	3053	excessive	T080	C0442802
27241818	3054	3064	peripheral	T082	C0205100
27241818	3065	3072	fatigue	T184	C0015672